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Tissue transglutaminase (TG2) enables survival of
human malignant pleural mesothelioma cells in
hypoxia
Sara Zonca1, Giulia Pinton1, Zhuo Wang2, Maria Felicia Soluri3, Daniela Tavian4, Martin Griffin2, Daniele Sblattero5 and Laura Moro*,1
Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to environmental/occupational exposure to asbestos,
characterized by the presence of significant areas of hypoxia. In this study, we firstly explored the expression and the role of
transglutaminase 2 (TG2) in MPM cell adaptation to hypoxia. We demonstrated that cells derived from biphasic MPM express the
full-length TG2 variant at higher levels than cells derived from epithelioid MPM and normal mesothelium. We observed a significant
induction of TG2 expression and activity when cells from biphasic MPM were grown as a monolayer in chronic hypoxia or packed
in spheroids, where the presence of a hypoxic core was demonstrated. We described that the hypoxic induction of TG2 was HIF-2
dependent. Importantly, TGM2-v1 silencing caused a marked and significant reduction of MPM cell viability in hypoxic conditions
when compared with normoxia. Notably, a TG2-selective irreversible inhibitor that reacts with the intracellular active form of TG2,
but not a non-cell-permeable inhibitor, significantly compromised cell viability in MPM spheroids. Understanding the expression
and function of TG2 in the adaptation to the hypoxic environment may provide useful information for novel promising therapeutic
options for MPM treatment.
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Malignant pleural mesothelioma (MPM) is an aggressive
tumor linked to exposure to asbestos fibers, arising from
mesothelial surfaces of the pleural cavity.1,2 Asbestos-related
diseases develop slowly and are often diagnosed in their later
stages, preventing many patients from achieving treatment at
the most crucial point of disease progression.3
Very few patients are eligible for curative surgical resection,
and radiation therapy has also demonstrated poor results,
rendering chemotherapy the treatment of choice.4
Standard chemotherapeutic regimens in MPM are the
combination of pemetrexed and cisplatin or carboplatin.
Nevertheless, MPM is often refractory to chemotherapeutic
agents, and treatment intent is mostly palliative.5–7
It is therefore necessary to acquire new insights into the
pathobiology of this disease to improve diagnosis and provide
targets for more effective therapeutic strategies.
Transglutaminase 2 (TG2) is the first identified member of a
family of structurally and functionally related proteins widely
distributed in different tissues and cell types.8
TG2 catalyses the Ca2+-dependent post-translational mod-
ifications of proteins by introducing covalent bonds between
free primary amine groups and peptide bound glutamine
residues. It also displays GTPase, ATPase, protein kinase and
protein disulfide-isomerase activity.9–12 In addition, TG2
mediates the interaction of integrins and syndecans13 with
fibronectin and crosslinks proteins of the extracellular matrix,
when it is externalized from cells.14 TG2 overexpression has
been observed in many tumors, including pancreatic, breast,
colon, ovarian, non-small cell lung cancers, glioblastoma and
melanoma,15–20 whereas no data are present in literature
concerning its expression and function in MPM.
Increased expression of TG2 in cancer cells has been linked
to drug resistance, metastasis and poor patient survival.21
Under physiological conditions, in the intracellular environ-
ment, there is low Ca2+ and a high GTP/GDP ratio and TG2 is
in an inactive form.22 Under stress conditions, TG2 can be
regulated by the activation of several signaling pathways or
epigenetic mechanisms.23 It has been demonstrated that
induced TG2 expression confers a growth advantage to
cancer cells to survive in hypoxic conditions.24 Hypoxia can
promote tumor progression and resistance to the effects of
chemotherapy and radiation; however, it is well known that it
can also inhibit tumor cell proliferation.25,26 Cellular adaptation
to micro-environmental hypoxia lets tumor cells undergo some
changes, including metabolic transformation. These adaptive
responses are mainly driven by HIFs, the hypoxia-inducible
transcription factors. HIFs are heterodimers comprising one of
three major oxygen labile HIF-α subunits (HIF-1α, HIF-2α or
HIF-3α) and a constitutive HIF-1β subunit (also known as aryl
hydrocarbon receptor nuclear translocator or ARNT), which
together form the HIF-1, HIF-2 and HIF-3 transcriptional
complexes, respectively.27 Intriguingly, it appears that in some
cell lines, HIF-1 drives the initial response to hypoxia while
during chronic hypoxic exposure it is HIF-2 that has the major
role in driving the hypoxic response.28–30 Recent studies
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confirmed thatMPM is a tumor with significant hypoxic areas in
the dominant tumor masses.31
TG2 has been described as undertaking important roles in
tumorigenesis, tumor differentiation and invasion, however a
role for TG2 in MPM has not been reported yet. In this study,
we measured TG2 expression and enzymatic activity in MPM
cell lines in the adaptation to the hypoxic environment.
Results
Constitutively spliced full-length TG2 is highly expressed
in MPM cell lines. The expression levels of the constitutively
spliced full-length TGM2-v1 and of four TGM2 variants (TGM2-
v2, v3, v4A, v4B), generated by alternative splicing,32 were
evaluated by real-time PCR in mesothelium and MPM derived
cell lines.
We demonstrated, by real-time PCR experiments, that the
constitutively spliced TGM2-v1 transcripts were increased in
REN and MSTO-211H cells, derived from epithelioid and
biphasic MPMs (9-fold and 22-fold increase, respectively) if
compared with mesothelial MET5A cells (Figure 1a). Notably,
the increased expression of the full-length TG2 in tumor cells
was confirmed at protein level, by western blot analysis
(Figure 1b).
TG2 expression and enzymatic activity increase and
prevent MSTO-211H cell death in hypoxia. To investigate
whether TG2 has an important role in MPM derived cells in
normoxic or hypoxic environments, we transiently transfected
TG2 siRNA into MSTO-211H cells, which express the highest
levels of the protein.
As shown in Figure 2a, TGM2-v1 silencing significantly
compromised cell viability in hypoxia, while exerting only a
moderate effect in normoxic condition. By western blot
analysis, shown in Figure 2b, we confirmed silencing and
evidenced an increase in PARP1 cleavage along with reduced
AKT phosphorylation in cells silenced for TGM2-v1, when
grown in hypoxia. On the contrary, we observed increased
proliferation in MSTO-211H cells transfected with an expres-
sion vector coding for (GFP)-TG2, cultured in hypoxia
(Supplementary Figure S1A and B). We next measured the
expression of TGM2-v1 transcript in MSTO211-H cells
cultured in normoxic or hypoxic conditions. TG2 was found
to be significantly upregulated at mRNA and protein level after
48 h of cell culture in hypoxia, when compared with normoxia
(Figure 2c and d). Furthermore, we assessed the transamidat-
ing activity in both conditions by incorporation of 5-(biotina-
mido)pentylamine (BAP) into proteins. As shown in Figure 2e,
transamidating activity was significantly enhanced in
MSTO-211H cells grown 48 h in hypoxic conditions compared
with cells grown in normal atmospheric oxygen concentration.
TG2 induced expression and its role in enabling cell survival in
hypoxia were observed in MET5A and REN cells too
(Supplementary Figure S2A and B).
TG2 expression depends on HIF-2 and is induced in the
hypoxic core of MSTO-211H spheroids. As observed by
us and reported in literature,30 HIF-2 has the major role in
driving response to chronic hypoxia. We tested the effect of
EPAS1 silencing on TGM2-v1 expression in MSTO-211H
cells cultured 48 h in hypoxia. Data, shown in Figure 3a,
confirm that the induction of TG2M-v1 expression was
dependent on HIF-2α. The EPAS1 induction in hypoxia and
its silencing were confirmed by semi-quantitative RT-PCR
(Figure 3b). Next, we cultured MSTO-211H cells, for 24, 48 or
72 h, as multicellular 3D spheroids. EPAS1 expression and
HIF-2α localization in the hypoxic core of spheroids at 72 h
were confirmed by RT-PCR and immunofluorescence stain-
ing with specific antibodies (Figure 3c and d). Parallel
induction of TGM2-v1 at 72 h in spheroids was assessed by
real-time PCR (Figure 3e). As shown in Figure 3f and g,
western blot analyses confirmed that both TG2 expression
and transamidating activity increased in spheroids at 72 h
compared to spheroids at 24 h. TG2 localization in spheroids
at 72 h was analyzed by immunofluorescence staining with
specific antibodies (Figure 3d).
TG2 silencing or intracellular inhibition compromises the
MSTO-211H cell viability in multicellular spheroids. We
next examined the effect of TGM2-v1 silencing in
MSTO-211H spheroids. As shown in Figure 4a, TGM2-v1
silencing significantly compromised cell viability in spheroids
that appeared reduced in size and dark in light microscopy.
Furthermore, TGM2-v1 silencing induced PARP1 cleavage
and reduced AKT phosphorylation, after 72 h (Figure 4b).
Remarkably, these results were reproduced by the use of
25 μM 1–155, a cell-permeable selective TG2 inhibitor
(Figure 4d and e), whereas no evident effects were observed
after incubation of spheroids with 25 μM of the non-cell-
permeable TG2 inhibitor R281 (Figure 4g and h). Further-
more, we assessed the transamidating activity in all
Figure 1 TG2 expression in mesothelium and mesothelioma derived cell lines.
(a) Real-time PCR analysis of TGM2-v1, TGM2-v2, TGM2-v3, TGM2-v4A and
TGM2-v4B mRNA in MET5A, REN and MSTO-211H cells. 18S rRNA was used as
housekeeping gene. Each bar represents mean of three independent experiments
±S.D. *P≤ 0.05, **P≤ 0.01. (b) Representative western blot analysis of TG2
expression in MET5A, REN and MSTO-211H cells. Tubulin was used as loading
control
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conditions, by incorporation of the competitive amine
substrate BAP into proteins. As shown in Figure 4c and f,
transamidating activity was significantly reduced in
MSTO-211H spheroids silenced for TG2 expression or
treated with 1–155 inhibitor, whereas it was not compromised
by incubation with the R281 inhibitor at the same concentra-
tion (Figure 4i). Transamidating activity was however abol-
ished when spheroids were incubated with a ten times (i.e.,
250 μM) higher dose of R281 (Supplementary Figure S3A),
even though neither spheroids viability nor PARP cleavage or
AKT phosphorylation resulted compromised (Supplementary
Figure S3B and C).
Discussion
In this study, we firstly describe that tumor cell lines derived
from MPM patients express higher basal levels of TG2
compared with normal mesothelial cells. Furthermore, we
show that in cells derived from biphasic MPM, the levels of
expressed TG2 and transamidating activity significantly
increase in response to chronic hypoxia.
Hypoxia is a common feature of solid tumors and is
associated with disease progression as well as resistance to
radiotherapy and chemotherapy.33,34 However, the presence
of hypoxic areas is a feature of cancer that can be exploited for
designing rational therapeutic approaches.35
Recently published data on hypoxia imaging provided
evidence that human MPMs are characterized by the
presence of significant areas of hypoxia.31 Differently from
other tumors in which the hypoxic condition induces epithelial-
mesenchymal transition and invasion,36,37 we have recently
described that hypoxia causes the switch from spindle to
epithelioid phenotype, along with reduced growth rate, in cells
derived from biphasic MPM.38
TG2 has crucial roles in a number of both physiological and
pathological events, which involve modifying its substrate
proteins.39 Numerous studies that investigated the putative
role of TG2 in cancers described the dual role of the protein
acting either as a facilitator or attenuator of cell proliferation.40
The evidence that TG2 is activated by reactive oxygen species
implies TG2 acts as a stress responder that may confer a
growth advantage to cancer cells to survive in micro-
environmental hypoxia.41
Figure 2 TG2 expression and enzymatic activity increase and prevent MSTO-211H cell death in hypoxia. (a) Bar graph shows the percentage of viable MSTO-211H cells
transfected with siRNA specific for TGM2-v1 (TG2 siRNA) versus non-specific siRNA (NS siRNA), cultured 48 h in normoxia (N) or hypoxia (H). Each bar represents mean of
three independent experiments± S.D. *P≤ 0.05, **P≤ 0.01. (b) Representative western blot analysis of PARP1, cleaved PARP1, pAKTand TG2 expression in MSTO-211H cells
transfected with non-specific siRNA (NS siRNA) or siRNA specific for TGM2-v1 (TG2 siRNA) and cultured 48 h in normoxia (N) or hypoxia (H). Tubulin was used as loading
control. (c) Real-time PCR analysis of TGM2-v1 mRNA in MSTO-211H cells cultured 48 h in normoxia (N) or hypoxia (H). 18S rRNA was used as housekeeping gene. Each bar
represents mean of three independent experiments±S.D. *P≤ 0.05. (d) Representative western blot analysis of TG2 expression in MSTO-211H cells cultured 48 h in normoxia
(N) or hypoxia (H). Tubulin was used as loading control. (e) Representative western blot of the TG2-catalyzed incorporation of 5-(biotinamido) pentylamine (BAP) into proteins in
MSTO-211H cells cultured 48 h in normoxia (N) or hypoxia (H)
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To investigate the effect of TG2 onMPMcells under hypoxia,
we established MPM hypoxic cell models in vitro, by placing
cells in an environmentally controlled chamber in which
oxygen levels in the gas phase were maintained at 1%.
Furthermore, we used multicellular spheroid as a 3D model
that accurately reproduces the oxygen and nutrient distribu-
tion of avascular tumor masses and measured the expression
and activity of TG2 at different time points. The results indicate
that, together with the enhanced expression of TG2 mRNA
and protein, transamidating activity also increased under
prolonged hypoxia.
The response to hypoxia is primarily mediated by the family
of HIF transcription factors, regulated by the oxygen-sensing
HIF hydroxylases.42 HIF-2α was initially identified as the
Figure 3 TG2 expression depends on HIF-2 and is induced in the hypoxic core of MSTO-211H spheroids. (a) Real-time PCR analysis of TG2M-v1 mRNA in MSTO-211H
cells transfected with non-specific siRNA or specific for EPAS1 (siRNA EPAS1) and cultured 48 h in normoxia (N) or hypoxia (H). 18S rRNA was used as housekeeping gene.
Each bar represents mean of three independent experiments± S.D. *P≤ 0.05. (b) Representative quantitative RT-PCR analysis of EPAS1 in MSTO-211H cells transfected with
non-specific control siRNA or EPAS1 specific siRNA (siRNA EPAS1) and cultured 48 h in normoxia (N) or hypoxia (H). 18S rRNA was used as housekeeping gene. (c)
Representative quantitative RT-PCR analysis of EPAS1 in MSTO-211H cells grown for 24, 48 or 72 h as spheroids (pools of 5). 18S rRNA was used as housekeeping gene. (d)
Phase contrast images and immunofluorescence analysis of HIF-2α and TG2 spatial distribution in MSTO-211H spheroids at 72 h, evidenced by FITC-conjugated secondary Abs
(×200 magnification). Bar equals 100 μM. (e) Real-time PCR analysis of TG2M-v1 mRNA in MSTO-211H cells grown 24, 48 or 72 h as spheroids. 18S rRNA was used as
housekeeping gene. Each bar represents mean of three independent experiments± S.D. *P≤ 0.05. (f) Representative western blot analysis of TG2 expression in MSTO-211H
cells grown 24 or 72 h as spheroids. Tubulin was used as loading control. (g) Representative western blot of the TG2-catalyzed incorporation of 5-(biotinamido) pentylamine
(BAP) into proteins in MSTO-211H cells grown 24 or 72 h as spheroids
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endothelial PAS domain protein, but it is also expressed in
many other tissues and exerts a widespread role in driving the
response during chronic hypoxia exposure.30
Our data demonstrate that TG2 expression is under the
control of HIF-2 and is crucial for the hypoxia response ofMPM
cells. In fact, gene silencing revealed only a minor role for TG2
in normoxia, whereas under hypoxic conditions cell viability
was severely compromised.
The reduction in AKT phosphorylation, along with the
increase in PARP1 cleavage, observed in both TGM2-v1-
silenced cells and 1–155 treated cells under hypoxia, is
suggestive of induced apoptosis. However, the regulatory
mechanisms of TG2 in cell death require additional studies.
Interestingly, downregulation of TG2 expression also occurred
in the 1–155 treated cells, suggesting that TG2 activity can
regulate its own expression in the MPM cells by a positive
Figure 4 TG2 silencing or intracellular inhibition compromises the MSTO-211H cell viability in multicellular spheroids. (a) Phase contrast images (×200 magnification) of
MSTO-211H cells transfected with non-specific siRNA (NS siRNA) or specific for TGM2-v1 (TG2 siRNA) and grown 72 h as spheroids. Bar equals 100 μM. (b) Representative
western blot analysis of PARP1, cleaved PARP1, pAKTand TG2 expression in MSTO-211H cells transfected with non-specific siRNA (NS siRNA) or specific for TGM2-v1 (TG2
siRNA) and grown 72 h as spheroids. Tubulin was used as loading control. (c) Representative western blot of the TG-catalyzed incorporation of 5-(biotinamido) pentylamine
(BAP) into proteins in MSTO-211H transfected with non-specific siRNA (NS siRNA) or specific for TGM2-v1 (TG2 siRNA) and grown 72 h as spheroids. (d) Phase contrast
images (×200 magnification) of MSTO-211H cells grown 72 h as spheroids± 25 μM 1–155. Bar equals 100 μM. (e) Representative western blot analysis of PARP1, cleaved
PARP1, pAKTand TG2 expression in MSTO-211H cells grown 72 h as spheroids± 25 μM 1–155. Tubulin was used as loading control. (f) Representative western blot of the
TG2-catalyzed incorporation of BAP into proteins in MSTO-211H cells grown 72 h as spheroids± 25 μM 1–155. (g) Phase contrast images (×200 magnification) of MSTO-211H
cells grown 72 h as spheroids± 25 μMR281. Bar equals 100 μM. (h) Representative western blot analysis of PARP1, cleaved PARP1, pAKTand TG2 expression in MSTO-211H
cells grown 72 h as spheroids± 25 μM R281. Tubulin was used as loading control. (i) Representative western blot of the TG2-catalyzed incorporation of BAP into proteins in
MSTO-211H cells grown 72 h as spheroids± 25 μM R281
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feedback mechanism. Such mechanisms involving either the
activation of TGF-β or NF-kB by TG2, which in turn regulate
TG2 expression have been reported by others and recently
reviewed by Huang et al.41
Furthermore, the significantly impaired transamidating
activity, observed in MSTO-211H spheroids silenced for
TGM2-v1 expression, is suggestive that the observed enzy-
matic activity is mainly mediated by this TG isoform.
Notably, the treatment with 1–155, a TG2-selective irrever-
sible inhibitor that can react with the intracellular active form of
the enzyme, significantly compromised MPM cell viability when
grown as spheroids. Moreover, it has been described that this
small-molecule inhibitor, which can react with TG2 inside the
cell, holding the enzyme in its open conformation, prevents its
export and translocation into the ECM, events which are
paralleled by a reduction in the deposition of the FNmatrix.43,44
Further studies, using high doses of the non-cell-permeable
R281 inhibitor, confirmed that the extracellular TG2-trans-
amidating activity does not have a role in preventing MPM cell
apoptosis under hypoxic stress. As recently suggested,45,46 our
data indicate that TG2 could act as a signaling/scaffold protein or
mediate some kind of activity that requires the closedGTP bound
conformation. However, at the moment we cannot fully rule out a
role for intracellular TG2-transamidating activity as it was
monitored by detecting BAP incorporation and we have no direct
evidence that this agent is cell permeating in our cell model.
In summary, our findings demonstrate that the expression
and function of TG2 has an important role in the adaptation of
MPMcell to hypoxia and therefore inhibition of TG2may provide
a novel therapeutic avenue for the treatment of this disease.
Materials and Methods
Reagents and antibodies. The polyclonal antibody specific for pAKTand the
monoclonal antibodies specific for PARP1, HIF-2α and α-tubulin were purchased
from Santa Cruz Biotechnology (Santa Cruz CA, USA). Anti-mouse and anti-rabbit
IgG peroxidase or fluorescein isothiocyanate (FITC)-conjugated antibodies and
chemical reagents were from Sigma-Aldrich (St Louis, MO, USA). Enhanced
chemiluminescence (ECL), nitrocellulose membranes and protein assay kit were
from Bio-Rad (Hercules, CA, USA). The monoclonal antibody specific for TG2
(TG100), culture media, sera, antibiotics and LipofectAMINE transfection reagent
were from Thermo Fisher (Waltham, MA, USA). The highly selective TG2 inhibitors,
1–155 (cell-permeable) and R281 (non-cell-permeable), were designed and
synthesized as previously documented.47,48
Cell cultures and transfection. The mesothelium derived MET5A and the
biphasic MPM MSTO-211H cell lines were obtained from the Istituto Scientifico Tumori
(IST) Cell-bank, Genoa, Italy; the epithelioid MPM REN cell line was isolated,
characterized and kindly provided by Dr Albelda SM (University of Pennsylvania,
Philadelphia; PA, USA). Cells were grown in standard conditions in RPMI medium
supplemented with 10% FBS, 100 μg/ml streptomycin and 10 μg/ml penicillin at 37 °C
in a humidified environment containing 5% CO2. Cell cultures under hypoxic conditions
were performed in 1% O2 gas mixture using a modulator incubator chamber.
Mycoplasma infection was excluded by the use of Mycoplasma PlusTM PCR Primer
Set kit from Stratagene (La Jolla, CA, USA). Cells grown to 80% confluence in tissue
culture dishes were transiently transfected with negative control or specific siRNAs
(1027416, 1027416) from Qiagen (Hilden, Germany) using LipofectAMINE reagent as
described by the manufacturer. Following treatments, cells were trypsinized and stained
with Trypan blue. The number of cells considered viable (unstained cells) was counted
in a Bürker haemocytometer within 5 min after staining.
Multicellular spheroids. Multicellular spheroids were generated in non-
adsorbent round-bottomed 96-well plates, as previously described.49 The 96-well
plates were coated with a 1 : 24 dilution of polyHEMA (120 mg/ml) in 95% ethanol
and dried at 37 °C for 24 h. Before use, plates were sterilized by UV light for 30 min.
For generation of multicellular spheroids, 5 × 103 cells were added into each well of
polyHEMA-coated 96-well plate and placed in a 37 °C humidified incubator with 5%
CO2. Every 24 h, 50% of supernatant was replaced with fresh medium± 1–155 or
R281 TG2 inhibitors (at final concentration of 25 μM).
Immunofluorescence staining. Cell spheroids were fixed in 4% paraf-
ormaldehyde, permeabilized with 0.5% Triton X-100 in PBS and blocked in 3% BSA/
PBS 10% FBS. The primary antibodies (mouse anti-HIF-2α or mouse anti TG2;
1 : 100) were incubated for 2 h at 4 °C. The fluorescent secondary antibody (rabbit
anti-mouse IgG antibody conjugated with FITC; 1 : 100) was added and incubated for
1 h at 4 °C. The cell nuclei were counter-stained with 4′,6-diamidino-2-phenylindole.
Fluorescent images were captured using a Leica MB5000B microscope equipped with
a DFC480 R2 digital camera and a Leica Application Suite (LAS) software.
Cell lysis and immunoblot. Cells were extracted with 1% NP-40 lysis buffer
(1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8.5 10 mM EDTA, 10 mM NaF,
10 mM Na4P2O7, 0.4 mM Na3VO4) with freshly added protease inhibitors (10 μg/ml
leupeptin, 4 μg/ml pepstatin and 0.1 Unit/ml aprotinin). Lysates were centrifuged at
13 000 × g for 10 minutes at 4 °C and the supernatants were collected and assayed
for protein concentration with the Bradford assay method (Bio-Rad).
Proteins were separated by SDS-PAGE under reducing conditions. Following
SDS-PAGE, proteins were transferred to nitrocellulose, reacted with specific
antibodies and then detected with peroxidase-conjugate secondary antibodies and
chemioluminescent ECL reagent. Digital images were taken with the Bio-Rad
ChemiDoc Touch Imaging System and quantified using Bio-Rad Image Lab 5.2.1.
Measurement of TG2 activity in intact cells. TG2 activity was dete-
rmined by pre-incubating cells, cultured in 2D or as spheroids, with 1 mM 5-bio-
tinamido-pentylamine, a competitive amine substrate of TG2, for 2 or 24 h at 37 °C.
Cells were then washed in PBS and lysed with 1% NP-40 lysis buffer and protein
content in the supernatant was quantified. Western blot analysis was performed on
the cell lysate with peroxidase-conjugate streptavidin and ECL reagent.
RNA isolation and Real-time PCR. Total RNA was extracted using the
guanidinium thiocyanate method. Starting from equal amounts of RNA, cDNA used
as template for amplification in the real-time PCR (5 μg), was synthesized by the
reverse transcription reaction using RevertAid Minus First Strand cDNA Synthesis
Kit from Fermentas-Thermo Scientific (Burlington, ON, Canada), using random
hexamers as primers, according to the manufacturer’s instructions. Twenty
nanogram of cDNA were used to perform RT-PCR amplification of EPAS1 mRNA.
The primers sequences for EPAS1 were: Fw 5′-GGGGATCAGCGCACAGAGTT-3′
and Rev 5′-TGGGCTGACGACAGGCTGTA-3′; 18S RNA was simultaneously
amplified using the primers: Fw 5′-AAACGGCTACCACATCCAAG-3′ and Rev
5′-CCTCCAATGGATCCTCGTTA-3′. The real-time reverse transcription-PCR was
performed using the double-stranded DNA-binding dye SYBR Green PCR Master
Mix (Fermentas-Thermo Scientific) on an ABI GeneAmp 7000 Sequence Detection
System machine, as described by the manufacturer. The instrument, for each gene
tested, obtained graphical cycle threshold (Ct) values automatically. Triplicate
reactions were performed for each marker and the melting curves were constructed
using Dissociation Curves Software (Applied Biosystems, Foster City, CA, USA), to
ensure that only a single product was amplified. We used the isoform specific
oligonucleotide primers pairs designed by Phatak VM et al.32 to selectively amplify
TGM2 transcripts.
Statistical analysis. Statistical evaluation of the differential analysis was
performed by one-way ANOVA and Student’s t-test.
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